Latanoprostene Bunod

Evidence Level: L5

Predicted Indications: 9

Latanoprostene Bunod

Pharmacist Assessment Report

Latanoprostene Bunod: From Open-Angle Glaucoma to Visceral Calciphylaxis

One-Sentence Summary

Latanoprostene bunod is an eye drop originally used to lower eye pressure in open-angle glaucoma and ocular hypertension. The TxGNN model predicts it may be effective for visceral calciphylaxis, but this is a computational prediction only, with 0 clinical trials and 0 publications directly supporting it.

Quick Overview

Item	Content
Original Indication	Open-angle glaucoma; ocular hypertension
Predicted New Indication	Visceral calciphylaxis
TxGNN Prediction Score	0.9976
Evidence Level	L5
Canada Market Status	Marketed (marketed DINs: 1 of 1)
Number of DINs	1 (marketed: 1)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the source record. Based on known information, latanoprostene bunod releases two active components: latanoprost acid, a prostaglandin F receptor (FP) agonist, and nitric oxide (NO), a vasodilator. Its efficacy in lowering eye pressure is established. The FP receptor (PTGFR) is its recorded pharmacological target.

The link to visceral calciphylaxis is speculative. NO/cGMP signalling may in theory counter vascular calcification. However, the drug is given as an eye drop, which produces very low exposure in the rest of the body. A systemic effect on a disease such as calciphylaxis is therefore implausible. The high score reflects model output, not clinical or mechanistic support.

Other top-ranked predictions in the data compiled for this report show the same pattern:

Thoracic outlet syndromes (venous, arterial, neurogenic), spontaneous coronary artery dissection, gastric angiodysplasia and lymphangiectasis: no credible mechanistic link and no clinical evidence.
Vascular disease and hemangioendothelioma: only indirect evidence, described below.

Clinical Trial Evidence

No clinical trials are registered for visceral calciphylaxis.

The only trial found for the broader predicted category “vascular disease” (rank 6) is shown below. It is about eye blood vessels, not systemic vascular disease, and offers only indirect information.

Trial Number	Phase	Status	Enrollment	Key Findings
NCT03931317	N/A	Completed	70	Randomized crossover study comparing latanoprostene bunod with timolol on retinal blood vessel density and visual acuity in ocular hypertension or primary open-angle glaucoma

Literature Evidence

No publications are available for visceral calciphylaxis.

Related publications found for other predicted indications:

PMID	Year	Type	Journal	Key Findings
30028313	2018	Review	Neural Regeneration Research	Overview of treatment options for glaucomatous optic neuropathy (for “vascular disease”; indirect)
38113361	2023	Case report	Ophthalmic Surgery, Lasers & Imaging Retina	An 11-year-old with a port-wine birthmark, choroidal haemangioma and glaucoma developed serous retinal detachment on prostaglandin analogues, including latanoprostene bunod. This is a possible adverse event, not a treatment benefit (for “hemangioendothelioma”)

Canada Market Information

DIN	Product Name	Dosage Form	Approved Indication
02484218	VYZULTA	Not specified	Not specified

Safety Considerations

Drug target: The drug acts on the prostanoid FP receptor (PTGFR). No other interacting drugs were identified.
Safety signal from the literature: A 2023 case report described serous retinal detachment in a child with a port-wine birthmark and choroidal haemangioma after prostaglandin analogue therapy, including latanoprostene bunod.

Please refer to the package insert for warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction for visceral calciphylaxis rests only on a model score. No trials or publications support it, and the mechanism is speculative. Eye-drop dosing gives minimal systemic exposure, so a systemic effect is unlikely.

To proceed, the following is needed:

Detailed mechanism of action data
Package insert warnings and contraindications from Health Canada
Evidence that a relevant drug level can be reached in the target tissue by an ocular or other route
Preclinical data on NO/cGMP and FP receptor effects on vascular calcification
If a nearer indication is of interest, specific evidence for primary hereditary glaucoma, including paediatric and congenital subtypes
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.